Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759968 | 0.88 | BRD4 (0.39) | BRD4ERBB2EPHA2EPHB4KDR | |
| SCHEMBL1759973 | 0.88 | BRD4 (0.39) | BRD4ERBB2EPHA2EPHB4KDR | |
| SCHEMBL7686350 | 0.85 | SPHK1 (0.41) | BRD4SPHK1KDM1AHSD11B2 | |
| SCHEMBL3617796 | 0.84 | SPHK1 (0.41) | BRD4SPHK1HSD11B2KMT2A | |
| SCHEMBL502795 | 0.84 | SPHK1 (0.41) | BRD4SPHK1HSD11B2SMN1; SMN2 | |
| SCHEMBL3617792 | 0.84 | SPHK1 (0.41) | BRD4SPHK1HSD11B2KMT2A | |
| SCHEMBL502794 | 0.84 | SPHK1 (0.41) | BRD4SPHK1HSD11B2SMN1; SMN2 | |
| SCHEMBL2695057 | 0.84 | BRD4 (0.39) | BRD4SPHK1HSD11B2KMT2A | |
| SCHEMBL2695063 | 0.84 | BRD4 (0.39) | BRD4SPHK1HSD11B2KMT2A | |
| SCHEMBL14350826 | 0.84 | SPHK1 (0.42) | BRD4SPHK1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023294-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Cognition Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3498692-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Cognition Therapeutics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3099296-B1 | ISOINDOLINE DERIVATIVE, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20170144970-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144970-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, PSD | OPRK1 62/4885BRD4 3840/4885SPHK1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.